Clinical Trials Logo
  1. Home
  2. Diabetes Mellitus, Type 2
  3. NCT02880267
  4. Details
NCT02880267 Clinical Trial

Effectiveness and Safety of the Dexcom™ G6 Continuous Glucose Monitoring System

Diabetes Mellitus Clinical Trial

Official title:
Effectiveness and Safety of the Dexcom™ G6 Continuous Glucose Monitoring System

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT02880267
Other study ID # PTL-902220
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 2016
Est. completion date September 2017

Study information
Verified date December 2018
Source DexCom, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Effectiveness and Safety of the Dexcom G6 Continuous Glucose Monitoring (CGM) System

Description:

The objective of the study is to establish performance of the System compared to a laboratory reference measurement. The effectiveness of the System will be evaluated by comparison of CGM values to a laboratory reference, Yellow Spring Instrument (YSI), using arterialized venous sample measurements. Performance will be evaluated in terms of point and rate accuracy of the System in reference to YSI.

The safety profile of the System will be characterized by the incidence of device-related Adverse Events (AEs) experienced by study subjects.

Recruitment information / eligibility
Status Completed
Enrollment 304
Est. completion date September 2017
Est. primary completion date July 2017
Accepts healthy volunteers No
Gender All
Age group 2 Years and older
Eligibility Inclusion Criteria:

- Ages 2 or older

- Diagnosis of Type 1 diabetes or Type 2 diabetes, on intensive insulin therapy

- Willing to participate in a clinic session involving venous sampling for evaluation of study end point

Exclusion Criteria:

- Use of acetaminophen

- Known allergy to medical-grade adhesives

- Pregnancy

- Hematocrit outside specification of the study-assigned blood glucose meter

Study Design

Related Conditions & MeSH terms

Intervention

Device:
• CGM
Glucose challenge during a clinic session to assess CGM performance compared to a laboratory reference measurement.

Locations
Country Name City State
United States Atlanta Diabetes Atlanta Georgia
United States Barbara Davis Center Aurora Colorado
United States Joslin Diabetes Center Boston Massachusetts
United States AMCR Institute Escondido California
United States Stanford Palo Alto California
United States Oregon Health Science University Portland Oregon
United States Sansum Santa Barbara California
United States Rainier Seattle Washington
United States Diablo Walnut Creek California

Sponsors (1)
Lead Sponsor Collaborator
DexCom, Inc.

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Proportion of blood glucose values, compared between CGM and a lab glucose analyzer that are matched relative to a proportion of blood glucose values, compared between CGM and a lab glucose analyzer matched to an accuracy measurement of %20/20 mg/dL 10 Days
See also
  Status Clinical Trial Phase
Completed NCT03743779 - Mastering Diabetes Pilot Study
Completed NCT03786978 - Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus N/A
Completed NCT01804803 - DIgital Assisted MONitoring for DiabeteS - I N/A
Completed NCT05039970 - A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04068272 - Safety of Bosentan in Type II Diabetic Patients Phase 1
Completed NCT03243383 - Readmission Prevention Pilot Trial in Diabetes Patients N/A
Completed NCT03730480 - User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS) N/A
Recruiting NCT02690467 - Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm. N/A
Completed NCT02229383 - Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus Phase 3
Completed NCT06181721 - Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT04489043 - Exercise, Prediabetes and Diabetes After Renal Transplantation. N/A
Withdrawn NCT03319784 - Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients Phase 4
Completed NCT03542084 - Endocrinology Auto-Triggered e-Consults N/A
Completed NCT02229396 - Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Phase 3
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT01892319 - An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Completed NCT05031000 - Blood Glucose Monitoring Systems: Discounter Versus Brand N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A